Literature DB >> 29371020

Liquid crystalline drug delivery vehicles for oral and IV/subcutaneous administration of poorly soluble (and soluble) drugs.

Andrew Otte1, Bong-Kwan Soh2, Gwangheum Yoon2, Kinam Park3.   

Abstract

Poorly soluble drug molecules often have low bioavailability issues and absorption problems in the clinical setting. As the number of poorly soluble drugs increases from discovery, developing technologies to enhance their solubility, while also controlling their release is one of the many challenges facing the pharmaceutical industry today. Liquid crystalline systems, nanoparticulate or macro-matrix, self-assemble in the presence of an aqueous environment and can provide a solubility enhancement, while also controlling the drug release rate. This review examines the fundamentals of liquid crystalline systems through the representative literature, concluding with examples of liquid crystalline systems in clinical trials development. The review focus is on the potential of utilizing liquid crystalline systems for poorly soluble drugs, in the areas of oral delivery and IV/subcutaneous, followed by water soluble molecules. Key considerations in utilizing liquid crystalline systems advantages while also discussing potential areas of key research that may be needed will be highlighted.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cubosome; Drug delivery; Hexosome; Liquid crystal; Poorly soluble drug

Mesh:

Year:  2018        PMID: 29371020     DOI: 10.1016/j.ijpharm.2018.01.037

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  3 in total

Review 1.  Liquid Crystalline Phases for Enhancement of Oral Bioavailability.

Authors:  Xingwang Zhang; Wei Wu
Journal:  AAPS PharmSciTech       Date:  2021-02-22       Impact factor: 3.246

Review 2.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

3.  Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.

Authors:  László Dézsi; Tamás Mészáros; Erik Őrfi; Tamás G Fülöp; Mark Hennies; László Rosivall; Péter Hamar; János Szebeni; Gábor Szénási
Journal:  Molecules       Date:  2019-09-09       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.